Get the Stockscreener App
24.33
0.41%
-0.10
After Hours:
24.06
-0.27
-1.11%
Syndax Pharmaceuticals Inc stock is traded at $24.33, with a volume of 1.46M.
It is down -0.41% in the last 24 hours and up +3.53% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$24.43
Open:
$24.49
24h Volume:
1.46M
Relative Volume:
1.09
Market Cap:
$2.15B
Revenue:
$172.60M
Net Income/Loss:
$-285.42M
P/E Ratio:
-7.381
EPS:
-3.2963
Net Cash Flow:
$-323.17M
1W Performance:
-0.94%
1M Performance:
+3.53%
6M Performance:
+61.77%
1Y Performance:
+114.74%
1-Day Range:
$23.88
$24.73
1-Week Range:
$23.88
$25.21
52-Week Range:
$8.58
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
24.33 | 2.15B | 172.60M | -285.42M | -323.17M | -3.2963 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | H.C. Wainwright | Buy |
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Liquidity Mapping Around (SNDX) Price Events - Stock Traders Daily
SNDX 260417 21.00C (SNDX260417C21000) Stock Options Chain | Quotes & News - Moomoo
SNDX SEC FilingsSyndax Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Update Recap: Can Syndax Pharmaceuticals Inc disrupt its industryRate Hike & Precise Swing Trade Alerts - baoquankhu1.vn
Syndax Pharmaceuticals Hits New 52-Week High - National Today
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 52-Week HighShould You Buy? - MarketBeat
Palumbo Wealth Management LLC Invests $1.08 Million in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
BTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, Niktimvo - MSN
Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Path To Profitability - 富途牛牛
US Market Wrap: Is Syndax Pharmaceuticals Inc a defensive stock2026 Buyback Activity & Consistent Return Investment Signals - baoquankhu1.vn
SNDX Technical Analysis & Stock Price Forecast - Intellectia AI
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
SG Americas Securities LLC Has $2.72 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc (1T3.MU) Analyst Insights, Price Targets & Recommendations - ca.finance.yahoo.com
Goldman Sachs Raises Price Target for SNDX to $34, Maintains 'Bu - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - MarketBeat
Why (SNDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
SNDX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Assenagon Asset Management S.A. - MarketBeat
MACD Signal: What makes Syndax Pharmaceuticals Inc stock attractive today2026 Recap & Consistent Profit Trade Alerts - baoquankhu1.vn
SNDX Should I Buy - Intellectia AI
SNDX Analyst Rating Update: Mizuho Lowers Price Target | SNDX St - GuruFocus
Mizuho Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $43 - Moomoo
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $43.00 by Analysts at Mizuho - MarketBeat
Hennion & Walsh Asset Management Inc. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Entry Recap: Is Syndax Pharmaceuticals Inc a good ESG investment2026 Price Momentum & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
SNDX: Jefferies Adjusts Syndax Pharmaceuticals Price Target to $40 | SNDX Stock News - GuruFocus
Jefferies Financial Group Reiterates "Buy" Rating for Syndax Pharmaceuticals (NASDAQ:SNDX) - MarketBeat
Mizuho lowers Syndax Pharmaceuticals stock price target on sales timing By Investing.com - Investing.com Canada
Syndax Pharmaceuticals Inc (1T3.SG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Jefferies cuts Syndax Pharmaceuticals stock price target on valuation By Investing.com - Investing.com Canada
Vanguard (NYSE) reports 0 shares in Syndax after realignment (SNDX) - Stock Titan
Syndax (SNDX) Q4 2025 Earnings Call Transcript - AOL.com
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template - ChartMill
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month HighWhat's Next? - MarketBeat
Earnings call transcript: Syndax Pharmaceuticals Q4 2025 revenue beats forecast, stock rises - Investing.com Canada
Hedge Fund Bets: Is Syndax Pharmaceuticals Inc stock showing strong momentumMarket Trend Summary & Daily Price Action Insights - baoquankhu1.vn
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Hudson Bay Capital Management LP - MarketBeat
CEO Moves: Can Syndax Pharmaceuticals Inc stock double in the next yearMarket Activity Report & Community Verified Watchlist Alerts - baoquankhu1.vn
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish - AOL.com
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset - AOL.com
DAFNA Capital Reduces Syndax Pharmaceuticals Holding in Q4 2025News and Statistics - IndexBox
Kynam Capital Sells $8.18M in Syndax Shares, Position Value RisesNews and Statistics - IndexBox
Biotech Shares Surge 72% with $8 Million Transaction, Yet This Is Why a Fund Remains Optimistic - Bitget
Understanding Momentum Shifts in (SNDX) - Stock Traders Daily
Syndax Pharmaceuticals stock hits 52-week high at 25.16 USD By Investing.com - Investing.com Canada
Can Syndax Pharmaceuticals Inc scale operations efficiently2026 News Drivers & Fast Moving Stock Watchlists - baoquankhu1.vn
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week HighWhat's Next? - MarketBeat
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):